
Opinion|Videos|January 16, 2024
Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
Advertisement
Episodes in this series

Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
The OncFive: Top Oncology Articles for the Week of 11/15
3
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
4
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
5

